Ebastine Teva 20 mg orodisp. tabl.

Country: Belġju

Lingwa: Ingliż

Sors: AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

Ixtrih issa

Ingredjent attiv:

Ebastine 20 mg

Disponibbli minn:

Teva Pharma Belgium SA-NV

Kodiċi ATC:

R06AX22

INN (Isem Internazzjonali):

Ebastine

Dożaġġ:

20 mg

Għamla farmaċewtika:

Orodispersible tablet

Kompożizzjoni:

Ebastine 20 mg

Rotta amministrattiva:

Oral use

Żona terapewtika:

Ebastine

Sommarju tal-prodott:

CTI code: 390634-08 - Pack size: 100 - Commercialisation status: YES - FMD code: 05407003822021 - CNK code: 2929248 - Delivery mode: Medical prescription; CTI code: 390634-04 - Pack size: 30 - Commercialisation status: YES - FMD code: 05407003822007 - CNK code: 2929222 - Delivery mode: Medical prescription; CTI code: 390634-05 - Pack size: 40 - Commercialisation status: NO - Delivery mode: Medical prescription; CTI code: 390634-06 - Pack size: 50 - Commercialisation status: YES - FMD code: 05407003822014 - CNK code: 2929230 - Delivery mode: Medical prescription; CTI code: 390634-07 - Pack size: 98 - Commercialisation status: NO - Delivery mode: Medical prescription; CTI code: 390634-01 - Pack size: 10 - Commercialisation status: NO - CNK code: 2929214 - Delivery mode: Medical prescription; CTI code: 390634-02 - Pack size: 15 - Commercialisation status: NO - Delivery mode: Medical prescription; CTI code: 390634-03 - Pack size: 20 - Commercialisation status: NO - Delivery mode: Medical prescription

L-istatus ta 'awtorizzazzjoni:

Commercialised: Yes

Data ta 'l-awtorizzazzjoni:

2011-04-15

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ġermaniż 20-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Franċiż 20-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Franċiż 20-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Olandiż 20-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Olandiż 20-04-2023

Fittex twissijiet relatati ma 'dan il-prodott